Evolving role of novel COVID-19 Medicine Delivery Units.

Integrated healthcare journal Pub Date : 2022-01-01 DOI:10.1136/ihj-2022-000135

Alice Packham, Niamh Spence, Anna Goodman

{"title":"Evolving role of novel COVID-19 Medicine Delivery Units.","authors":"Alice Packham, Niamh Spence, Anna Goodman","doi":"10.1136/ihj-2022-000135","DOIUrl":null,"url":null,"abstract":"The COMET-ICE trial showed a relative risk reduction of 85% (p=0.0002) in rates and hospitalisation and death compared with placebo.3 Overall, sotrovimab has an excellent tolerability and safety profile with minimal drug interactions, making it suitable for most patients. Severely immunocompromised patients are unlikely to have a robust immune response either to COVID-19 infection or previous COVID-19 vaccination.15 Variation between immunocompromised subgroups has been noted, with the lowest levels of vaccine efficacy in organ or stem cell transplant recipients.16 Immunocompromised patients potentially have much to gain from sotrovimab and other antivirals. Early in vitro assays suggest the same may occur to sotrovimab, with far lower impact on the increasingly dominant Omicron variant BA.2.17 The United States Food and Drug Administration (FDA) no longer recommends sotrovimab in any US region due to the increased proportion of cases caused by BA.2.18 It remains in use in the UK at present. According to the clinical commissioning guidelines, sotrovimab can be used in pregnancy, and remdesivir requires a risk–benefit clinical assessment.","PeriodicalId":73393,"journal":{"name":"Integrated healthcare journal","volume":"4 1","pages":"e000135"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/a9/ihj-2022-000135.PMC10241034.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrated healthcare journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ihj-2022-000135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The COMET-ICE trial showed a relative risk reduction of 85% (p=0.0002) in rates and hospitalisation and death compared with placebo.3 Overall, sotrovimab has an excellent tolerability and safety profile with minimal drug interactions, making it suitable for most patients. Severely immunocompromised patients are unlikely to have a robust immune response either to COVID-19 infection or previous COVID-19 vaccination.15 Variation between immunocompromised subgroups has been noted, with the lowest levels of vaccine efficacy in organ or stem cell transplant recipients.16 Immunocompromised patients potentially have much to gain from sotrovimab and other antivirals. Early in vitro assays suggest the same may occur to sotrovimab, with far lower impact on the increasingly dominant Omicron variant BA.2.17 The United States Food and Drug Administration (FDA) no longer recommends sotrovimab in any US region due to the increased proportion of cases caused by BA.2.18 It remains in use in the UK at present. According to the clinical commissioning guidelines, sotrovimab can be used in pregnancy, and remdesivir requires a risk–benefit clinical assessment.

Abstract Image